← back to search

Peng Xiu

Shandong First Medical University · CN
Area of research
Cancer Research · Hepatology
Research interest
Research interests include Cancer, Lipids, and Metabolism, Hepatocellular Carcinoma Treatment and Prognosis, Cancer, Hypoxia, and Metabolism, and Inflammatory mediators and NSAID effects.
h-index
19
citations
1,111
works
40
NIH funding
primary concept
Medicine
email

Recent publications

The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma
Scientific Reports 2021cited by 75position: lastdoi
circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis
Cell Cycle 2019cited by 74position: middledoi
Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
Journal of Experimental & Clinical Cancer Research 2018cited by 118position: lastdoi
Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways
Scientific Reports 2018cited by 31position: middledoi
Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the <scp>YAP</scp>‐<scp>TEAD</scp> complex
Cancer Science 2016cited by 214position: middledoi
Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway
Oncology Reports 2016cited by 35position: middledoi
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
PLoS ONE 2014cited by 46position: middledoi
Downregulating sCLU Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Gemcitabine by Activating the Intrinsic Apoptosis Pathway
Digestive Diseases and Sciences 2014cited by 18position: firstdoi
Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma
Cancer Science 2012cited by 61position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jie Li · Jiamusi University7 papers (2012–2019)Xueying Sun · Medical College of Wisconsin6 papers (2012–2018)Zongzhen Xu · Shandong University6 papers (2012–2019)Xiaofeng Dong · Shandong University3 papers (2012–2016)Hongchi Jiang · Nanjing University of Chinese Medicine3 papers (2012–2018)Feng Liu · Shandong University3 papers (2012–2016)Jingtao Zhong · Shandong University3 papers (2016–2021)Honglong Wei · Shandong University3 papers (2016–2021)Xuesong Dong · Shandong University2 papers (2012–2014)Bo Zhai · Zhejiang Chinese Medical University2 papers (2012–2014)Fuhai Wang · Shandong University2 papers (2016–2016)Xin Wang · Hunan University2 papers (2016–2019)Bingqi Liu · Shandong University2 papers (2018–2019)Guangsheng Yang · Shandong University2 papers (2018–2019)Xiaona Yu · Shandong University1 papers (2018–2018)Wenjing Jiang · Nanchang University1 papers (2018–2018)Yaxun Guo · Shandong University1 papers (2021–2021)Xian Jiang · Sichuan University1 papers (2018–2018)Haiquan Qiao · Harbin Medical University1 papers (2014–2014)Zhihua Lu · Shandong University1 papers (2019–2019)